At present, osimertinib is a treatment choice for patients with EGFR mutation-positive advanced NSCLC in the first-line setting, and for patients with T790M positive NSCLC following disease progression after first-line EGFR-TKIs12,14. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.